ENTITY
Jinxin Fertility

Jinxin Fertility (1951 HK)

126
Analysis
Health Care • China
Jinxin Fertility Group is a leading international provider of assisted reproductive services (ARS) and assisted reproductive technology (ART). Its core offerings include In Vitro Fertilization (IVF), Intrauterine Insemination (IUI), egg retrieval, embryo transfer, and genetic screening, alongside a range of women's health services. The company is headquartered in Chengdu, China, and was founded in 1951.
more
•22 Feb 2021 17:17

Asia Short Interest: Lenovo, AIA, Nongfu, Wuxi Bio, Toshiba, Freee, Canon, Samsung, Celltrion, TSMC

The Insight looks at large short interest movements across HK, Japan, Korea and Taiwan stocks and highlights large increases/decreases in shorts to...

Logo
385 Views
Share
•16 Feb 2021 18:11

Asia Short Interest: WuXi Bio, PSBC, Jinxin Fertility, BYD, Ryohin, Freee, Itochu, Pearl Abyss

The Insight looks at large short interest movements across HK, Japan, Korea and Taiwan stocks and highlights large increases/decreases in shorts to...

Logo
377 Views
Share
•07 Feb 2021 15:13

Suzhou Basecare Medical IPO: Trading Debut

Basecare priced its IPO at HK$27.36 and closed 14% up at HK$31.20 in the grey market. Our DCF sensitivity analysis shows that the IPO price is...

Logo
470 Views
Share
•01 Feb 2021 18:58

Jinxin Fertility (锦欣生殖) Placement - Setting up for Acquisitions

Jinxin Fertility Co Ltd (1951 HK) is looking to raise US$167m in its top-up placement to fund potential acquisitions in China and Southeast Asia.

Share
•24 Jan 2021 21:22

Suzhou Basecare Medical IPO Initiation: Improving IVF

Basecare is pre-marketing for an HK IPO to raise $250 million. With a large addressable market opportunity and Basecare’s early mover advantage, we...

Logo
623 Views
Share
x